GPER-L1

From WikiMD's Wellness Encyclopedia


Introduction[edit | edit source]

GPER-L1 (G Protein-Coupled Estrogen Receptor 1) is a G protein-coupled receptor (GPCR) that is activated by estrogen. It is also known as GPR30. GPER-L1 is distinct from the classical nuclear estrogen receptors, ERα and ERβ, and is involved in rapid non-genomic signaling pathways.

Structure[edit | edit source]

GPER-L1 is a member of the GPCR family, which is characterized by seven transmembrane domains. These receptors are integral membrane proteins that transduce extracellular signals through the activation of intracellular G proteins. The structure of GPER-L1 allows it to interact with various ligands, including estrogen, and initiate signaling cascades within the cell.

Function[edit | edit source]

GPER-L1 mediates a variety of physiological processes through its ability to bind estrogen and activate downstream signaling pathways. These pathways include the activation of adenylyl cyclase, leading to increased levels of cyclic AMP (cAMP), and the activation of phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. These signaling events can result in diverse cellular responses, such as cell proliferation, apoptosis, and migration.

Role in Cardiovascular System[edit | edit source]

In the cardiovascular system, GPER-L1 has been shown to mediate vasodilation and protect against vascular injury. It is involved in the regulation of blood pressure and has potential implications in the treatment of hypertension.

Role in Cancer[edit | edit source]

GPER-L1 is implicated in the progression of certain types of cancer, including breast cancer and ovarian cancer. It can influence cancer cell proliferation and survival, making it a potential target for therapeutic intervention.

Clinical Significance[edit | edit source]

The discovery of GPER-L1 has expanded the understanding of estrogen signaling beyond the classical nuclear receptors. It offers new insights into the mechanisms of estrogen action in various tissues and has potential implications for the development of novel therapeutic agents targeting estrogen-related diseases.

Research and Development[edit | edit source]

Ongoing research is focused on elucidating the precise mechanisms of GPER-L1 signaling and its role in health and disease. The development of selective GPER-L1 agonists and antagonists is an area of active investigation, with the aim of modulating its activity for therapeutic benefit.

Also see[edit | edit source]

References[edit | edit source]

External links[edit | edit source]





WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD